Nearly half of voters in eight big European Union countries want to be able to vote on whether to remain members of the bloc, just as Britons will in a referendum next month, according to a new opinion poll.
45% of over 6,000 people surveyed in Belgium, France, Germany, Hungary, Italy, Poland, Spain and Sweden said they wanted their own vote.
A third would opt to leave the EU if given the chance, poll firm Ipsos-MORI said.
The size of the potential "Out" vote ranges from as high as 48% and 41% in Italy and France respectively to as low as 22% and 26% in Poland and Spain, the firm said.
Italy's anti-establishment 5-Star Movement has grown into the country's second-biggest political force, and wants an exit from the euro currency zone.
France's hard-right National Front party also wants to drop the single currency.
The Ipsos-MORI online poll found that 49% of people in the eight countries thought Britain would vote to leave the EU on June 23, higher than the number in Britain itself, which stood at 35%, the survey showed.
51% said Brexit would hurt the EU's economy, while only 36% thought it would hurt Britain's.
UK "Out" campaigners have said the country would be in a strong position in any negotiations on a new trade deal after leaving the bloc, given its standing as the world's fifth-biggest economy.
The "Out" campaign has also warned that the EU is destined for deeper political union, but the Ipsos-MORI poll showed few voters in Europe think that is likely.
Just over 20% of respondents in all nine EU countries covered by the survey, including Britain, thought there would be more integration by 2020 compared with 40% who thought there would be less.
48% of voters thought a Brexit vote next month would result in other countries also leaving the bloc, compared with 18% who disagreed.
The poll was conducted between March 25 and April 8.
Pharma body says Brexit could leave UK patients facing drug delays
Meanwhile, the UK pharmaceuticals trade body has come out firmly against the country leaving the European Union, warning today that an exit could put British patients at the back of the queue for new medicines.
Leaders of individual companies, including GlaxoSmithKline's Andrew Witty and AstraZeneca's Pascal Soriot, have already voiced opposition to a so-called Brexit.
But the Association of the British Pharmaceutical Industry (ABPI) had not previously expressed a view.
ABPI CEO Mike Thompson, however, said that his members were "overwhelmingly supportive of remaining in the EU", especially given concerns over disruption to the pan-European drug approval system provided by the European Medicines Agency (EMA).
"If we left the EU, this would mean that the licensing of new medicines would have to be handled by a UK agency as well as a European agency," he said.
"Our members have confirmed that the applications for a UK licence would come after the European licence due to the smaller patient population in the UK," he added.
Lawyers have previously warned that a vote to leave the EU in Britain's referendum next month would threaten some prescription medicines with regulatory limbo.
An exit could also force the London-based EMA and the life sciences division of Europe's new Unified Patent Court to move from London.